Analyst Price Target is $77.40
▲ +24.80% Upside Potential
This price target is based on 6 analysts offering 12 month price targets for Prestige Consumer Healthcare in the last 3 months. The average price target is $77.40, with a high forecast of $104.00 and a low forecast of $70.00. The average price target represents a 24.80% upside from the last price of $62.02.
Current Consensus is
The current consensus among 6 contributing investment analysts is to buy stock in Prestige Consumer Healthcare. This rating has held steady since May 2022, when it changed from a Hold consensus rating.
Prestige Consumer Healthcare, Inc. engages in the marketing, sale, and distribution of pharmaceutical drugs and consumer products. It operates through the following segments: North American OTC Healthcare and International OTC Healthcare. The North American and International OTC Healthcare segments manages the following brands: BC/Goody's, Beano, Boudreaux's Butt Paste, Chloraseptic, Clear Eyes, Compound W, Debrox, DenTek, Dramamine, Efferdent, Fess, Fleet, Gaviscon, Hydralyte, Luden's, Monistat, Nix, Pedia-Lax, and Summer's Eve. The company was founded in 1996 and is headquartered in Tarrytown, NY.